IngentaConnect Attitudes and treatment outcome of breast conservation therapy fo...

Authors: Deo, SV Suryanarayana¹; Mohanti, Bidhu K²; Shukla, Nootan K¹; Chawla, Sheema²; Raina, Vinod³; Julka, Pramod K²; Rath, Gouya K²

Source: Australasian Radiology, Volume 45, Number 1, February 2001 , pp. 35-38(4)

Publisher: Blackwell Publishing

Abstract:

SUMMARY

Breast conservation therapy for early breast cancer is an established but grossly under-utilized treatment option in India for various reasons. Breast conservation therapy was offered to 200 suitable breast cancer patients between June 1993 and June 1998. Fifty-one patients (25%) opted for breast conservation and the remaining preferred mastectomy. In patients agreeing to conservation therapy, surgery was performed first along with peroperative implantation of iridium-192 to deliver a boost. Whole breast irradiation of 45 Gy was delivered 3-4 weeks after the boost. Cosmesis was assessed at the end of 6 months from completion of therapy. The main reason for refusal of breast conservation therapy was fear of recurrence in the remaining breast (60%). There were no locoregional failures in our study at a median follow up of 42 months; one patient experienced a systemic relapse. Cosmesis was good to excellent in 80% of patients. Breast conservation therapy using peroperative iridium-192 implant provides excellent locoregional disease control and cosmesis. The results of our study indicate that patient preference for mastectomy is an important reason for the under-utilization of breast conservation therapy in India.

Keywords: breast conservation therapy; early breast cancer; iridium-192

Document Type: Research article

DOI: 10.1046/j.1440-1673.2001.00870.x

Affiliations: 1: Surgical Oncology, 2: Radiation Oncology and 3: Medical Oncology, Institute Rotary Cancer Hospital, All India Institute Of Medical Sciences, New Delhi, India

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Attitudes and treatment outcome of breast conservation therapy for stage I & II breast cancer using peroperative iridium-192 implant boost to the tumour bed